ClinicalTrials.gg
Status unknownNCT00109655Updated Oct 3, 2008

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

A Phase 1 interventional study of Oncolytic adenovirus (serotype 5) - CG0070 in Carcinoma, Transitional Cell and Bladder Neoplasms, sponsored by Cell Genesys. Status unknown at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-10-03.

Sponsored by Cell Genesys · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2008), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 360 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 140 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Planned enrollment
129th of 333
75 · median 46
Started
2005
with 2 others
Phase 1
114 of 360
21 open now
Registered
6th of 360
by date

Among the 360 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 129th largest by planned enrollment of the 333 interventional ones that give a count, is one of 3 that started in 2005, is one of 114 in phase 1, and was the 6th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 360 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this research study is to evaluate the safety and dosing of CG0070.

Read the detailed description

Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.

03

Conditions studied

  • Carcinoma, Transitional Cell
  • Bladder Neoplasms

Keywords

  • Superficial Transitional Cell Carcinoma
  • Bacillus Calmette-Guerin (BCG)
  • Superficial Bladder Cancer
  • Gene Therapy
  • Vaccine
  • Adenovirus
  • Carcinoma in situ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High grade non-muscle invasive bladder cancer (stages Ta, T1 and/or CIS - carcinoma in situ). High grade being defined as G2 or G3 disease.
  • Failure of at least one prior treatment with BCG, defined as evidence of TCC on cystoscopic exam and or cystoscopic exam and urine cytology at least 6 weeks from last BCG treatment
  • performance status 0-1
  • Adequate bone marrow, renal, liver and coagulation function

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing
  • positive
  • Use of anticoagulants such as coumadin or heparin
  • History of bleeding disorder
  • Active systemic disease or chronic immunodeficiency
  • Prior gene therapy
  • Uncontrolled cystitis, bladder pain, bladder spasms, urinary incontinence, or reduced bladder volume
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    1

    Biological: Oncolytic adenovirus (serotype 5) - CG0070

Interventions

  • BiologicalOncolytic adenovirus (serotype 5) - CG0070

    Intravesical administration of CG0070 (in suspension) directly into the bladder

06

What researchers measure

Primary outcomes

  1. Maximum-tolerated or maximum feasible dose in single and multidose regimens of CG0070 by intravesical administration

    Time frame: Study End

Secondary outcomes

  1. Assessment of the amount of CG0070 in the urine and blood over time by PCR

    Time frame: Study End

07

Study locations

10 sites
  • BCG Oncology
    Phoenix, Arizona 85032, United States
  • UCSF Comprehensive Cancer Center
    San Francisco, California 94143, United States
  • Billings Clinic
    Billings, Montana 59107, United States
  • New York Oncology Hematology
    Albany, New York 12208, United States
  • Columbia University
    New York, New York 10032, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Mary Crowley Medical Research Center
    Dallas, Texas 75246, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Male/Female Health and Research Centre
    Barrie, Ontario L4M 7G1, Canada
  • The Fe/Male Health Centre
    Oakville, Ontario L6H 3P1, Canada
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Oct 2008 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2005
First posted
May 3, 2005
Start
Apr 2005
Primary completionEst.
Oct 2008
CompletionEst.
Sep 2010
Last update
Oct 3, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00109655
Lead sponsor
Cell Genesys
First posted
May 3, 2005
Start date
Apr 2005
Primary completion
Oct 2008 (estimated)
Completion
Sep 2010 (estimated)
Last update
Oct 3, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion